We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
Read MoreHide Full Article
Key Takeaways
10x Genomics won over $4.8M after a jury found Parse willfully infringed three licensed patents.
The jury upheld all three patents, reinforcing 10x Genomics' single-cell analysis IP portfolio.
10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent U.S. injunction.
10x Genomics, Inc. (TXG - Free Report) recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen (QGEN - Free Report) subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, upheld the patents' validity and awarded damages to TXG.
From an investor's perspective, the ruling reinforces 10x Genomics' intellectual property position in the single-cell analysis market and could support additional financial recovery through post-trial proceedings. Investors will likely watch whether the company secures enhanced damages or further protections for its technology in the U.S. market.
Likely Trend of TXG Stock Following the News
However, following the announcement, shares of TXG slipped more than 5% on Friday. Year to date, shares of the company have surged 277.4% compared with the industry’s 11.4% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
In the long run, the verdict could strengthen 10x Genomics' competitive position by reinforcing the value of its single-cell sequencing intellectual property portfolio, a key differentiator in the genomics market. If the company secures enhanced damages or a permanent injunction in post-trial proceedings, it could discourage future infringement, protect market share and support continued investment in innovation across its expanding single-cell and spatial biology businesses.
TXG currently has a market capitalization of $8.02 billion.
Image Source: Zacks Investment Research
Details of the News
The U.S. District Court for the District of Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, which became part of 10x Genomics in 2025. The patents, originally licensed from Roche Sequencing Solutions, cover foundational single-cell analysis technologies. Importantly, the jury rejected Parse's invalidity arguments and upheld the validity and enforceability of all three patents, strengthening 10x Genomics' intellectual property portfolio in the fast-growing genomics space.
The lawsuit centered on Parse's Evercode Whole Transcriptome products, with the jury concluding that infringing sales occurred from February 2021 through June 30, 2026. Based on a 14% royalty rate on those sales, the jury awarded more than $4.8 million in damages to 10x Genomics. The ruling follows a patent dispute that had been unfolding in Delaware federal court since 2022, making it one of the notable intellectual property battles in the single-cell sequencing market.
What's Next for Qiagen's Parse Business?
The legal process is not over yet. In post-trial proceedings, 10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent injunction that would prevent Parse from continuing to sell the infringing products in the United States. For Qiagen, the next phase of the case could determine whether Parse must modify its U.S. product strategy, secure licensing arrangements or pursue additional legal options as the court considers the requested remedies.
Industry Prospects Favoring the Market
Per a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.
Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.
Recently, 10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.
Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products.
TXG’s Zacks Rank & Key Picks
Currently, TXG has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
Key Takeaways
10x Genomics, Inc. (TXG - Free Report) recently secured a favorable jury verdict in its patent infringement case against Parse Biosciences, a Qiagen (QGEN - Free Report) subsidiary. The Delaware jury found Parse infringed three patents licensed to Scale Biosciences, upheld the patents' validity and awarded damages to TXG.
From an investor's perspective, the ruling reinforces 10x Genomics' intellectual property position in the single-cell analysis market and could support additional financial recovery through post-trial proceedings. Investors will likely watch whether the company secures enhanced damages or further protections for its technology in the U.S. market.
Likely Trend of TXG Stock Following the News
However, following the announcement, shares of TXG slipped more than 5% on Friday. Year to date, shares of the company have surged 277.4% compared with the industry’s 11.4% growth. However, the S&P 500 has risen 12.3% in the same timeframe.
In the long run, the verdict could strengthen 10x Genomics' competitive position by reinforcing the value of its single-cell sequencing intellectual property portfolio, a key differentiator in the genomics market. If the company secures enhanced damages or a permanent injunction in post-trial proceedings, it could discourage future infringement, protect market share and support continued investment in innovation across its expanding single-cell and spatial biology businesses.
TXG currently has a market capitalization of $8.02 billion.
Image Source: Zacks Investment Research
Details of the News
The U.S. District Court for the District of Delaware found that Parse Biosciences, now a Qiagen subsidiary, willfully infringed three patents exclusively licensed to Scale Biosciences, which became part of 10x Genomics in 2025. The patents, originally licensed from Roche Sequencing Solutions, cover foundational single-cell analysis technologies. Importantly, the jury rejected Parse's invalidity arguments and upheld the validity and enforceability of all three patents, strengthening 10x Genomics' intellectual property portfolio in the fast-growing genomics space.
The lawsuit centered on Parse's Evercode Whole Transcriptome products, with the jury concluding that infringing sales occurred from February 2021 through June 30, 2026. Based on a 14% royalty rate on those sales, the jury awarded more than $4.8 million in damages to 10x Genomics. The ruling follows a patent dispute that had been unfolding in Delaware federal court since 2022, making it one of the notable intellectual property battles in the single-cell sequencing market.
What's Next for Qiagen's Parse Business?
The legal process is not over yet. In post-trial proceedings, 10x Genomics plans to seek enhanced damages, attorneys' fees and a permanent injunction that would prevent Parse from continuing to sell the infringing products in the United States. For Qiagen, the next phase of the case could determine whether Parse must modify its U.S. product strategy, secure licensing arrangements or pursue additional legal options as the court considers the requested remedies.
Industry Prospects Favoring the Market
Per a report by Custom Market Insights, the global spatial biology market size is estimated at $1.48 billion in 2026 and is anticipated to reach $7.24 billion by 2035, expanding at a CAGR of 19.2% from 2026 to 2035.
Growth in spatial biology is driven by the rising demand for single-cell and tissue-level insights to better understand complex diseases like cancer. Expanding use in drug discovery, precision medicine and AI-driven research, along with advances in high-throughput sequencing technologies, is accelerating market adoption.
10x Genomics Price
10x Genomics price | 10x Genomics Quote
Other News
Recently, 10x Genomics exited the second quarter of 2026 with better-than-expected results, as both earnings and revenues beat the Zacks Consensus Estimate. Reported revenues declined year over year due to lower non-recurring license and royalty revenues. However, the underlying business remained resilient. Products and Services revenues increased, supported by growth in Single Cell and Spatial consumables and higher services revenues. Gross margin expansion was another positive, although the company swung to an operating loss from year-ago operating income.
Atera remained the key development in the quarter. Customer response was strong, with booked orders at the end of the second quarter already well above the roughly 40 instruments previously expected for 2026. TXG continues to expect shipments of around 40 units this year as manufacturing capacity ramps. The company expects Atera-related transition dynamics to weigh on third-quarter revenues as customers moderate purchases of existing Spatial products.
TXG’s Zacks Rank & Key Picks
Currently, TXG has a Zacks Rank #3 (Hold).
A couple of better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.